INS and Hepatic steatosis: In patients with drug-naive T2DM, liver fat content can be significantly decreased irrespective of using exenatide, insulin, or pioglitazone therapy. Early metabolic control, including glycemic control and weight reduction, plays an important role in slowing progression of fatty liver in T2DM.